Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Data Shares Rise on Plans for 3-for-2 Stock Split

NEW YORK (GenomeWeb News) - Clinical Data’s board of directors yesterday approved a 3-for-2 stock split that will give company stockholders one new share of common stock for every two shares they own.
 
The news drove the company's share price up nearly 13 percent to close at $34.38 yesterday. In late morning trading today, the company's shares had pulled back slightly to $33.96. 
 
The split will occur Sept. 24, and the dividends will be distributed on Oct. 2, the company said.
 
When the split is complete, the company will have a total of around $20.5 million shares outstanding.
 
Company President and CEO Drew Fromkin said the split "reflects the confidence we have in the prospects of our company," and said it is "an opportunity to broaden our base of investors by making our stock more accessible while improving its liquidity.”

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.